![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Omnaris, others |
Other names | (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a607008 |
Pregnancy category |
|
Routes of administration | Nasal inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.210.908 |
Chemical and physical data | |
Formula | C32H44O7 |
Molar mass | 540.697 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings. [6]
It was patented in 1990 and approved for medical use in 2005. [7] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. [8] It is on the World Health Organization's List of Essential Medicines. [9]
It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Omnaris, others |
Other names | (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a607008 |
Pregnancy category |
|
Routes of administration | Nasal inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.210.908 |
Chemical and physical data | |
Formula | C32H44O7 |
Molar mass | 540.697 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings. [6]
It was patented in 1990 and approved for medical use in 2005. [7] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. [8] It is on the World Health Organization's List of Essential Medicines. [9]
It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.